Limantrafin clinical trials
Also written CB-103.
How each study uses limantrafin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the limantrafin studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- CB-103
- 4
Studies by the year they started
4 studies that test it; most in 2023 (2)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2021 | 1 |
| 2023 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 1 · Other 3
Michael J. Dennis, MD (1) · M.D. Anderson Cancer Center (1) · Cellestia Biotech AG (1) · MedSIR (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test limantrafin.
- Jun 2027CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACCPhase 1/2 · Michael J. Dennis, MD
Studies
Open first, then newest update. How each study uses limantrafin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACCRecruitingPhase 1/2Michael J. Dennis, MDNCT05774899Written as CB-103
- Phase II Study to Evaluate Safety and Efficacy of CB-103 With Venetoclax in Adolescent and Young Adult Patients With Relapsed/Refractory T-ALL or T-LBLTerminatedPhase 2M.D. Anderson Cancer CenterNCT05464836Written as CB-103
- Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological MalignanciesTerminatedPhase 1/2Cellestia Biotech AGNCT03422679Written as CB-103
- CB-103 Plus NSAI In Luminal Advanced Breast CancerTerminatedPhase 2MedSIRNCT04714619Written as CB-103
Codes
What other systems call limantrafin · ClinicalTrials.gg INT017645
- UNII (FDA) Q5BB91JL0VLIMANTRAFINOne source FDA
- NCI Thesaurus C175580LimantrafinOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | Q5BB91JL0V | LIMANTRAFIN | One source FDA |
| NCI Thesaurus | C175580 | Limantrafin | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.